on behalf of the DissolVE-2 investigators* BACKGROUND: Limited data exist on VTE risk and prophylaxis in Chinese inpatients. The Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism-2 (DissolVE-2), a nationwide, multicenter, cross-sectional study, was therefore designed to investigate prevalence of VTE risks and evaluate VTE prophylaxis implementation compliant with the latest prophylaxis guidelines (American College of Chest Physicians [CHEST], 9th edition).
VTE affects approximately 5% to 15% of patients hospitalized for medical or surgical complaints. 1 The incidence of DVT and pulmonary embolism in the Chinese population (Hong Kong) is estimated to have increased from 17.1 and 3.9, respectively, per 100,000 in 2000 to 2001 2 to 30.0 and 8.7 per 100,000
in 2010 to 2011. 3 This approximate doubling in incidence is probably due to multiple factors, including lifestyle changes, longer life span, heightened VTE awareness, and advances in imaging availability and expertise. 3, 4 Although early VTE prophylaxis is recommended, [5] [6] [7] [8] [9] [10] it is reportedly clinically underutilized. 11 The multicenter Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting (ENDORSE) study reported that 51.8% of hospitalized patients were at risk of VTE, with only one half of those receiving prophylaxis complying with the American College of Chest Physicians (CHEST) guidelines, 7th edition. Although ENDORSE excluded China and Japan, other Asian ENDORSE substudies reported a VTE risk similar to that of the global population (50.4%). However, CHEST-adherent VTE prophylaxis was lower than the overall average (32.1%). [12] [13] [14] In 2016, there were, on average, 6,321,000 medical and surgical inpatients in China on a daily basis 15 at risk for hospital-acquired VTE. Concern with their VTE-related risk and management should take into account their thrombosis and bleeding risk profiles and frequency of VTE prophylaxis administration, none of which, to the best of our knowledge, has been studied in detail. The VTE Risk Assessment and Thromboprophylaxis Among Hospitalized Acute Medical Patients in China (RAMP) study 16 included ICU and coronary care unit (CCU) patients and showed that the proportion of at-risk patients in China was 57.3%. In addition, only 20.2% of these patients received CHEST-recommended VTE prophylaxis (CCU patients, 22.7%; ICU patients, 16.9%; P ¼ .0117). However, this study omitted non-ICU inpatients and reported on 1,247 patients, approximately 0.02% of China's current daily inpatient census. To understand VTE's real-world scenario in China, a nationally representative study was required. We therefore designed and conducted the Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism-2 (DissolVE-2) study to identify VTE and bleeding risk factors, estimate the proportions of at-risk hospitalized patients, and report the proportions receiving CHEST-compliant VTE prophylaxis in a large sample of medical and surgical inpatients. DissolVE-2 further evaluated VTE risk by using a combination of risk factor evaluation and prevalent contemporary risk-assessment modeling to facilitate comparisons with survey results from elsewhere.
Patients and Methods

Study Design
DissolVE-2 was a multicenter, observational, cross-sectional study (ChiCTR-OOC-16010187) that screened patients for eligibility between March and September 2016 in 44 major cities at 60 major hospitals with > 500 beds. These hospitals provide high-level services, medical education, and research 17 in six regions (Northeast, North, East, Northwest, Southwest, and South Central China) ( Fig 1A) . The ratio of included hospitals in each region's capital and noncapital cities was 1:1.
The study was conducted in accordance with the Declaration of Helsinki (1964) , its subsequent revisions, and Chinese Good Clinical Practice guidelines. The ethics committees of all sites approved the study protocol; however, the requirement of obtaining consent for any research utilizing patients' medical information was waived because this study was retrospective in nature.
Patients and Procedures
The sample size calculation is based on estimation of the prevalence of hospital-acquired VTE risk at the ward level. Assuming the lowest proportion of VTE risk ward patients to be approximately 0.03, to assess the true prevalence of VTE risk at 50% with a precision of AE5%, a minimum of 402 patients had to be evaluated using the Clopper-Pearson exact method. 18 Hence, the sample size was estimated as follows: 402/0.03 ¼ 13,400. We estimated that each center had to enroll approximately 230 patients to obtain this sample size.
Patients from general medicine, cardiac, neurovascular, oncology, respiratory, rheumatic, and the general surgical and orthopedic wards were included. Patients from the following wards were excluded: psychiatric; maternity; pediatric; ear, nose, and throat; burn; dermatology; ophthalmology; chronic; rehabilitation; and palliative care. Data from eligible patients' medical charts were collected by using an electronic case report, de-identified, and entered into an electronic data capture system by trained data management personnel. The abstracted data included demographic information, admission and discharge diagnoses, treatment/ procedural details, risk factors for bleeding and VTE present during hospitalization, and type of VTE prophylaxis administered as described in the CHEST guidelines, 9th edition. [7] [8] [9] We did not use the latest guidelines (10th edition) 19 because it contains updates for VTE treatment only and not prophylaxis.
Adult inpatients (hospitalized for $ 72 h) from eligible wards were screened. Inclusion criteria were treatment for acute illnesses such as an infectious, cardiac, or respiratory disease, or cancer according to the CHEST guidelines, 8th and 9th editions 6, 7 ; surgery, CHEST guidelines, 9th edition 8, 9 ; or a major traumatic experience that did not require surgery. Exclusion criteria were admission for diagnostic testing, hemodialysis, same-day surgery, pregnancy, or a chronic condition; VTE treatment # 24 h of admission; or admission to an ineligible ward.
VTE risk was evaluated in acute medical and surgical patients via the Padua Prediction Score or Caprini Risk Assessment model, respectively (e-Appendix 1; e-Tables 1-3). The risk factors were evaluated during admission, 72 h following admission, and prior to discharge for medical patients, and during admission, 24 h following operation, and prior to discharge for surgical patients. Dynamic evaluations were further conducted if the patient's situation changed depending on the VTE and bleeding risk. Medical patients were classified into low or high risk, while surgical patients were classified into very low, low, moderate, and high risk as defined by using the CHEST guidelines, 9th edition. [7] [8] [9] Subgroup analyses of VTE risk according to disease and surgery type were also performed. Patients were categorized as high risk or not at risk of major bleeding complications according to the criteria defined in the CHEST guidelines, 9th edition. Information on bleeding events and their associated reasons were obtained from medical records. Taking VTE and major bleeding risk into account, the proportion of at-risk patients receiving CHEST-recommended prophylaxis [7] [8] [9] was evaluated throughout the duration of the patients' stay. The prophylaxis received was categorized as any VTE or appropriate prophylaxis. Appropriate prophylaxis was defined as prophylaxis compliant with the CHEST guidelines, 9th edition. The occurrence of symptomatic VTE during hospitalization was also assessed as an exploratory objective.
Statistical Analyses
Continuous variables are presented as the number of observations, mean, SD, minimum, and maximum; categorical variables are presented as the number and percentage of the population. Distribution of hospitalized patients at various VTE risk levels, the prophylaxis received, and the distribution of in-hospital VTE events are summarized separately for medical and surgical patients in terms of percentage with 95% CIs. Statistical analyses were performed by using SAS version 9.4 (SAS Institute, Inc).
Results
Baseline Characteristics
From the 14,000 eligible patients, 13,609 (mean age, 56.7 AE 16.8 years; 52.6% female) were included in the full analysis set (Fig 1B) . Mean duration of hospitalization was 14.4 AE 11.1 days for the overall population, 14.4 AE 11.6 days for surgical patients, and 14.3 AE 10.6 days for medical patients (Table 1) . Surgical patients largely underwent general and abdominal-pelvic surgery (72.7%), whereas medical patients mainly experienced acute infection (32.4%) and active cancer (23.2%) ( Table 2) .
VTE Risk Stratification and Risk Factors
A total of 6,155 (45.2%; 95% CI, 44.4-46.0) patients from the overall population were deemed to be at high risk for VTE. Figure 2A shows that such patients were greater in the surgical group (53.4%; 95% CI, 52.2-54.6) than in the medical group (36.6%; 95% CI, 35. 4-37.8) . Orthopedic (100%; 95% CI, 99.8-100) and bariatric (100%; 95% CI, 91.7-100) surgery patients had the highest VTE risk among surgical patients; congestive heart failure (54.9%; 95% CI, 50.9-58.9) patients had the highest VTE risk among medical patients (e-Appendix 2; e- Table 4 ).
The major VTE risk factor in surgical patients was major open surgery (52.6%); acute infection and/or rheumatologic disorder (42.2%) was the major VTE risk factor in medical patients (Table 3 ). In total, 1,695 (24.3%), 1,852 (26.5%), 1,506 (21.6%), and 1,328 (19.0%) surgical patients, and 2,275 (34.3%), 1,236 (18.7%), 334 (5.0%), and 57 (0.9%) medical patients, reported carrying two to five or more VTE risk factors, respectively.
Bleeding Risk Factors
A high risk of major bleeding was present in 3,472 (25.5%) patients overall (2,766 surgical patients [39.6%] ; 706 medical patients [10.7%] ). Major bleeding risk factors in surgical patients were concomitant use of nonsteroidal antiinflammatory drugs (13.5%) and abdominal surgery (12.8%), whereas in medical patients, these factors were cancer (24.4%), rheumatic disease (6.1%), and age $ 85 years (6.0%) ( Table 4) .
Administration of VTE Prophylaxis
VTE prophylaxis was evaluated considering VTE and major bleeding risk simultaneously. Patients who were at risk but did not require prophylaxis were not excluded. Hence, 13,609 patients were included in the analysis of any prophylaxis administration. However, such patients were excluded while analyzing administration of appropriate prophylaxis. Any VTE prophylaxis was administered to 1,942 patients (14.3%; 95% CI, , which included 984 high-risk surgical patients (26.4%; 95% CI, and 312 high-risk medical patients (12.9%; 95% CI, 11.5-14.2) ( Table 5) . From the 971 patients who received the appropriate VTE prophylactic method (10.3%; 95% CI, , 608 were high-risk surgical patients (16.3%; 95% CI, , and 146 were high-risk medical patients (6.0%; 95% CI, 5.1-7.0). Figure 2B shows the overall picture of VTE prophylaxis administration in Chinese hospitals, stratified according to type of inpatient. The geographical stratification of appropriate VTE prophylaxis administration ranging from 0.8% (95% CI, 0.4-1.5) in Northeast China to 4.9% (95% CI, 4.0-6.05) in North China is shown in e-Appendix 3; e- prophylaxis administration to high-risk medical and surgical patients was highest in the Northwest (4.9%; 95% CI, 2.0-9.8) and North (7.6%; 95% CI, 5.9-9.5) China, respectively.
Distribution of VTE Events During Hospitalization
VTE events during hospitalization occurred in 44 inpatients overall (0.3%; 95% CI, 0.2-0.4), with the incidence for surgical (n ¼ 21) and medical (n ¼ 23) inpatients being similar (0.3%; 95% CI, 0.2-0.5). VTE events occurred more frequently in the high-risk VTE group than in the low-to moderate-risk groups for both medical (0.7% [95% CI, 0. 
Discussion
To our knowledge, this analysis is the first multicenter study to systematically investigate the current real-world status of VTE risk levels and prophylaxis in hospitalized Chinese patients. We found that the majority of admitted surgical and medical patients were at risk of VTE. Furthermore, many of these patients did not receive CHEST-recommended 7-9 VTE prophylaxis, thus illustrating a large real-world gap between mostly Western consensus evidence-based guidelines and current Chinese clinical practice.
A key difference exists between ENDORSE 11 -a large, multinational, observational study assessing VTE risk and its prophylaxis in hospitalized patients-and the present study. ENDORSE used CHEST, 7th edition, 20 guidelines (which evaluated VTE risk utilizing disease or surgical factors), whereas the present study used CHEST, 9th edition, [7] [8] [9] guidelines (which recommended the Caprini and Padua models for VTE risk evaluation). Utilization of modern methods in our study may have increased the accuracy of risk detection compared with ENDORSE. 11 Moreover, because ENDORSE excluded
China (approximately 20% of the world's population), our findings might fill the gap left by ENDORSE. We also identified a unique profile of VTE risk factors such as major surgery (52.6%) in surgical patients and acute infection and/or rheumatologic disorder (42.2%) in medical patients. Overall, 58.9% of patients had > 2 VTE risk factors. In contrast, the ENDORSE study reported chronic pulmonary disease, chronic heart failure, and obesity at the time of hospitalization, and immobilization during hospitalization, to be the most frequent risk factors in both medical and surgical patients. These differences may have occurred largely due to variations in profiles and races. Moreover, ENDORSE evaluated inpatients from a particular ward/floor only on a single day, which might have precluded accurate estimation of VTE risk factors. Interestingly, despite the distinct eligible populations, the RAMP study, 16 in concordance with our findings, reported that 57.3% of Chinese ICU/ CCU patients had $ 2 VTE risk factors.
Any prophylaxis administration (19.0% vs 9.3%) was probably higher in surgical patients than in medical CCU ¼ coronary care unit; GFR ¼ glomerular filtration rate; NSAID ¼ nonsteroidal antiinflammatory drug.
chestjournal.org patients because research has shown a higher risk of VTE in patients undergoing surgery. 21 Furthermore, any type of prophylaxis was administered to orthopedic surgery patients the most (66.4%), probably because they have the highest risk of VTE, 22 and orthopedists are highly aware of VTE prevention.
At-risk patients in ENDORSE 11 received nearly five times more CHEST-recommended prophylaxis than those in DissolVE-2 (50.2% vs 10.3%). Furthermore, the implementation of appropriate prophylaxis (3.6%) was far lower than previous observations. 23, 24 In Canada, approximately 16% of acutely ill patients received appropriate prophylaxis, 25 whereas in the Venous Thromboembolism Prophylaxis in Intensive Care Unit Patients (VOICE) study, 31.2% of patients received pharmacologic treatment and 44.2% received a combination of pharmacologic and mechanical prophylaxis. 22 The disparity in CHEST-recommended prophylaxis between DissolVE-2 and other studies could have occurred because we stringently defined "CHESTrecommended prophylaxis," after considering key elements in a prophylaxis course such as initiation time, modalities, and duration.
Only 14.3% of at-risk patients received some form of prophylaxis, with approximately 10.3% receiving the "correct'' prophylactic method. The trend of appropriate prophylaxis being administered to at-risk patients was observed even after geographical stratification, suggesting physicians across China are like-minded. These implementation rates suggest that physicians are aware of VTE risks but often do not comply with guideline recommendations, probably due to lack of medical education and enforcement or due to genuine concerns regarding the relevance of foreign guidelines to Chinese patients.
Estimating the distribution of VTE events during hospitalization was our exploratory objective. The incidence of in-hospital VTE reported in the present study (0.3%) is higher than values reported in the United Kingdom (0.21% in 2010 to 0.14% in 2016) 26 but similar to that of the United States (0.3%). 27 These findings imply that the current VTE prevention strategies are far less than optimal and also have some crucial implications for health-care resource planning.
The results of DissolVE-2 may be of significance from several perspectives. The gap between recommended and administered VTE prophylaxis can garner attention from both practitioners and hospital management, leading to enhanced medical education regarding inhospital VTE prophylaxis and interventions to make VTE risk-assessment systems at the ward or hospital level mandatory. Chinese local academic associations can also consider and revise their guidelines or consensus based on the current data. From the national health-care perspective, DissolVE-2 will contribute significant insights to the decision-making capabilities of the current health-care system in China, as well as reinforce action regarding resource planning because it can be an important reference to prospectively study the burden of thrombosis and bleeding risk associated with prophylaxis or its absence.
There are a few limitations in our study. DissolVE-2 was conducted retrospectively and hence was unable to determine causal inferences between VTE risk level and obtaining appropriate prophylaxis. Moreover, patient chart data instead of interview data were used, which could have caused some inaccuracies in obtaining the latest information. The hospitals chosen for this study 13,609 (14.3; 13.7-14.9) 971 /9,411 (10.3; 9.7-10.9) Surgical patients 1,326 /6,986 (19.0; 18.1-19.9) 825/6,986 (11.8; 11.0-12.6) Very low . . 44/971 (4.5; 3.2-5.9) 18/971 (1.9; 1.0-2.8)
Low
Moderate 298/2,285 (13.0; 11.6-14.4) 199/2,285 (8.7; 7.5-9.9) High 984/3,730 (26.4; 25.0-27.8) 608/3,730 (16.3; 15.1-17.5) Medical patients 616/6,623 (9.3; 8.65-10.0) 146/2,425 (6.0; 5.1-7.0) Low 304 /4,198 (7.2; 6.4-8.0 ) . 312/2,425 (12.9; 11.5-14.2) 146/2,425 (6.0; 5.1-7.0) No. ¼ number of patients who received the prophylaxis; N a ¼ number of patients who had any VTE risk; N b ¼ number of patients who needed to receive appropriate prophylaxis as per the CHEST guidelines, 9th edition (among surgical patients, all other patients except those at a very low risk needed to receive prophylaxis; among medical patients, only high-risk patients needed to receive prophylaxis).
High
represented the best care available in China and thus might not depict the general level of care given. Considering China's population density, there was a positive skew toward the inclusion of hospitals from South and East China compared with the Northwestern region. Moreover, patient data from several provinces were lacking, which if added, might potentially change the results. Bleeding risk factors were analyzed for the whole cohort and not after stratifying the patients on the basis of VTE risk. Hence, we cannot interpret the risk factors based on the risk level.
Conclusions
The DissolVE-2 study provided a nationwide perspective on the real-world clinical practice of VTE risk assessment and prophylaxis implementation in China. It showed that although a considerable proportion of medical and surgical patients are at risk of VTE, implementation of VTE prophylaxis is low, especially in medical patients. Furthermore, these findings highlight the need for greater awareness and actions from both physicians and the government to tackle the growing burden of VTE.
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